New insights into the pathophysiological role for cytokines in heart failure

Cardiovascular Research

Volumn 42, Issue 3, 1999, Pages 557-564

  Sasayama, Shigetake ^a   Matsumori, Akira ^a   Kihara, Yasuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CAPTOPRIL; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; PENTOXIFYLLINE; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

HEART DILATATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE OVERLOAD; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKINS; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032991345     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00050-4     Document Type: Review

References (65)

1. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
2. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
3. Kubota T., McNamara D.M., Wang J.J., et al. For the VEST Investigators for TNF Genotype Analysis: Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation. 97:1998;2499-2501.
4. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 79:1997;1128-1131.
5. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., Seta Y., Oral H., Spinale F.G., Mann D.L. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
6. Yamada T., Matsumori A., Sasayama S. Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 89:1994;846-851.
7. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., Demetris A.J., Feldman A.M. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α Circ Res. 81:1997;627-635.
8. Bryant D., Becker L., Richardson J., Shelton J., Franco F., Peshock R., Thompson M., Giroir B. Cardiac function in transgenic mice with myocardial expression of tumor necrosis factor-α Circulation. 97:1998;1375-1381.
9. Kapadia S.R., Oral H., Lee J., Nakano M., Taffet G.E., Mann D.L. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res. 81:1997;187-195.
10. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757.
11. Balligand J.L., Ungureanu-Longrois D., Simmons W.W., Pimental D., Malinski T.A., Kapturczak M., Taha Z., Lowenstein C.J., Davidoff A.J., Kelly R.A., Smith T.W., Michel T. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem. 269:1994;27580-27588.
12. Oyama J., Shimokawa H., Momii H., Cheng X., Fukuyama N., Arai Y., Egashira K., Nakazawa H., Tekeshita A. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest. 101:1998;2207-2214.
13. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
14. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
15. Oral H., Mann D.L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem. 272:1997;4836-4842.
16. Krown K.A., Page M.T., Nguyen C., Zechner D., Gutierrez V., Comstock K.L., Glembotski C.C., Quintana P.J.E., Sabbadini R.A. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 98:1996;2854-2865.
17. Matsumori A., Matoba Y., Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 92:1995;2519-2525.
18. Matsumori A. Animal models: Pathological findings and therapeutic considerations. Banatvala J.E. Viral Infections of the Heart. 1993;110-137 Edward Arnold, London.
19. Shioi T., Matsumori A., Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 94:1996;2930-2937.
20. Torre-Amione G., Kapadia S., Lee J., Durand J.-B., Bies R.D., Young J.B., Mann D.L. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
21. Francis S.E., Holden H., Holt C.M., Duff G.W. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 30:1998;215-223.
22. Lodge P.A., Herzum M., Olszewski J., Huber S.A. Coxsackievirus B-3 myocarditis: acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 128:1987;455-463.
23. Yokoyama T., Nakano M., Bednarczyk J.L., McIntyre B.W., Entman M., Mann D.L. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 95:1997;1247-1252.
24. Kishimoto C., Kuroki Y., Hiraoka Y., Ochiai H., Kurokawa M., Sasayama S. Cytokine and murine coxsackievirus B3 myocarditis: interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation. 89:1994;2836-2842.
25. Inoko M., Kihara Y., Morii I., Fujiwara H., Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol. 267:1994;H2471-H2482.
26. Shioi T., Matsumori A., Kihara Y., Inoko M., Ono K., Iwanaga Y., Yamada T., Iwasaki A., Matushima K., Sasayama S. Increased expression of interleukin-1 β and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 81:1997;664-671.
27. Arai K.I., Lee F., Miyajima A., Miyatake S., Arai N., Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 59:1990;783-836.
28. Aukrust P., Ueland T., Müller F., Andreassen A.K., Nordøy I., Aas H., Kjekshus J., Simonsen S., Frøland S.S., Gullestad L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 97:1998;1136-1143.
29. Matsumori A., Furukawa Y., Hashimoto T., Yoshida A., Ono K., Shioi T., Okada M., Iwasaki A., Nishio R., Matsushima K., Sasayama S. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 29:1997;419-423.
30. Okada M., Matsumori A., Ono K., Furukawa Y., Shioi T., Iwasaki A., Matsushima K., Sasayama S. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;894-901.
31. Chappell D.C., Varner S.E., Nerem R.M., Medford R.M., Alexander R.W. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res. 82:1998;532-539.
32. Vandenburgh H.H. Mechanical forces and their second messengers in stimulating cell growth in vitro. Am J Physiol. 262:1992;R350-R355.
33. Clark E.A., Brugge J.S. Integrins and signal transduction pathways: the road taken. Science. 268:1995;233-239.
34. Yamazaki T., Komuro I., Kudoh S., Inagaki K., Yoneda T., Kaburagi S., Araki M., Sasayama S. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 77:1995;258-265.
35. Iwanaga Y., Kihara Y., Hasegawa K. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation. 98:1998;2065-2073.
36. Vemulapalli S., Chiu P.J.S., Griscti K., Brown A., Kurowski S., Sybertz E.J. Phosphoramidon does not inhibit endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia in rats. Eur J Pharmacol. 257:1994;95-102.
37. McDonald K.M. Prevention of ventricular remodeling. J Lab Clin Med. 131:1998;124-129.
38. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts. Possible implication in left ventricular remodeling. Circulation. 98:1998;149-156.
39. Thaik C.M., Calderone A., Takahashi N., Colucci W.S. Interleukin-1 β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 96:1995;1093-1099.
40. Palmer J.N., Hartogensis W.E., Patten M., Fortuin F.D., Long C.S. Interleukin-1 β induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest. 95:1995;2555-2564.
41. Tsujino M., Hirata Y., Imai T., Kanno K., Eguchi S., Ito H., Marumo F. Induction of nitric oxide synthase gene by interleukin-1 β in cultured rat cardiocytes. Circulation. 90:1994;375-383.
42. Kacimi R., Long C.S., Karliner J.S. Chronic hypoxia modulates the interleukin-1 β stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation. 96:1997;1937-1943.
43. Hosenpud J.D., Campbell S.M., Pan G. Indirect inhibition of myocyte RNA and protein synthesis by interleukin-1. J Mol Cell Cardiol. 22:1990;213-225.
44. Sasayama S. Immune modulation of cardiac function: a new frontier. Role of the immune system in cardiac dysfunction. J Cardiac Fail. 1:1995;331-335.
45. Sasayama S. For OPC-8212 multicenter Research Group: A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther. 4:1990;419-426.
46. Feldman A.M., Bristow M.R., Parmley W.W., et al. For the Vesnarinone Study Group: Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
47. Sasayama S., Matsumori A. Vesnarinone: a potential cytokine inhibitor. J Cardiac Fail. 2:1996;251-258.
48. Matsui S., Matsumori A., Matoba Y., Uchida A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest. 94:1994;1212-1217.
49. Shioi T., Matsumori A., Matsui S., Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes. T cell line, and monocytic cell line. Life Sci. 54:1994;PL11-16.
50. Nishio R., Matsumori A., Shioi T., Wang W., Yamada T., Ono K., Sasayama S. Denopamine, a β1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. J Am Coll Cardiol. 32:1998;808-815.
51. Lin C.S., Boltz R.C., Blake J.T., Nguyen M., Talento A., Fischer P.A., Springer M.S., Sigal N.H., Slaughter R.S., Garcia M.L., Kaczorowski G.J., Koo G.C. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med. 177:1993;637-645.
52. + currents in cytotoxic T lymphocytes. Circ Res. 78:1996;253-261.
53. Wagner D.R., Combes A., McTiernan C., Sanders V.J., Lemster B., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-α Circ Res. 82:1998;47-56.
54. Kitakaze M., Minamino T., Funaya H., Node K., Shinozaki Y., Mori H., Hori M. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation. 95:1997;2108-2114.
55. Feldman A. et al., for the VesT Investigators: Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VesT). J Am Coll Cardiol 2,64A, 1997 (Abstract).
56. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336,525-533, 1997.
57. Matsumori A., Ono K., Nishio R., Igata H., Shioi T., Matsui S., Furukawa Y., Iwasaki A., Nose Y., Sasayama S. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation. 96:1997;1501-1506.
58. Massie B.M., Fisher S.G., Deedwania P.C., et al. For the CHF-STAT Investigators: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 93:1996;2128-2134.
59. Matsumori A., Ono K., Nishio R., Nose Y., Sasayama S. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation. 96:1997;1386-1389.
60. Packer M., O'Connor C.M., Ghali J.K., Shioi T., Okada I., Matsui S., Sato Y., Suzuki H., Shiota K., Sasayama S. For the PRAISE Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
61. Wang W.Z., Matsumori A., Yamada T., et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation. 95:1997;245-251.
62. Mohler III E.R., Sorensen L.C., Ghali J.K., Schocken D.D., Willis P.W., Bowers J.A., Cropp A.B., Pressler M.L. Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. J Am Coll Cardiol. 30:1997;35-41.
63. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093.
64. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 71:1993;3C-11C.
65. Peeters A.C.T.M., Netea M.G., Kullberg B.J., Thien T., Van der Meer J.W.M. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology. 94:1998;376-379.